Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Januvia Gains Indication For Initial Diabetes Treatment With Metformin

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Labeling for Merck’s DPP-4 inhibitor is also updated to include additional new regimens, as well as warning on hypersensitivity reactions.

You may also be interested in...



Novo Nordisk’s Liraglutide Set For March 2009 PDUFA

Phase II study of once-weekly GLP-1 analog is under way, with results due next year.

Novo Nordisk’s Liraglutide Set For March 2009 PDUFA

Phase II study of once-weekly GLP-1 analog is under way, with results due next year.

Merck Gets Janumet Label Extended

Combo drug’s new indications follow similar extensions last year for the pair when taken in tandem.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest News

Evusheld: UK Urged To Use RWD To Give Clinically Vulnerable Early Access To COVID-19 Treatment

OIG Accelerated Approval Report Spotlights Financial Costs Ahead Of Congressional Debate

Amylyx's Relyvrio: The Road To Regulatory Flexibility And US FDA Approval

How Will Approval Of Amylyx’s Relyvrio Impact The Ongoing PHOENIX Trial?

See All
UsernamePublicRestriction

Register

PS065208

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By